Roivant is a biopharmaceutical company that develops and commercializes medicines through a distinctive "Vant" subsidiary model, where independent companies with entrepreneurial management teams operate with their own equity incentives while sharing centralized capital allocation and support functions. The company builds its pipeline by in-licensing promising drug programs across therapeutic areas and deploying proprietary computational technologies to accelerate development. Its core revenue sources include milestone payments from pharma partners, royalties on net sales of approved drugs, and collaboration revenues from technology licensing partnerships, with current clinical programs targeting autoimmune and respiratory diseases including dermatomyositis, rheumatoid arthritis, myasthenia gravis, and pulmonary hypertension.